Alnylam-q3-2025 Earnings Appendix - GAAP与非GAAP对账表

Sep 3, 2026

Appendix provides GAAP to non-GAAP reconciliations for selected financial measures for Alnylam Pharmaceuticals, Inc., covering research and development expenses, selling, general and administrative expenses, operating income (loss), and net income (loss). Adjustments focus on stock-based compensation and related reconciling items such as marketable equity securities impacts, convertible debt losses, and income tax effects. The appendix also includes constant-currency analysis for product revenue growth metrics, showing reported growth, foreign currency translation impact, and growth at constant currency for total TTR, total Rare, net product revenue, and total revenue.

LanguageEnglish

CategoryGeneral

FormatPDF

Pages3

Reading Time1 min

AccessFree to download

Reconciliation of Selected GAAP Measures to Non-GAAP Measures

Reconciliation of GAAP to Non-GAAP Research and development expenses

Reconciliation of GAAP to Non-GAAP Selling, general and administrative expenses

Reconciliation of GAAP to Non-GAAP Income (loss) from operations

Reconciliation of GAAP to Non-GAAP Net income (loss)

Reconciliation of Product Revenue and Growth at Constant Currency

Appendix |I Alnylam Pharmaceuticals,Inc. # Reconciliation of Selected GAAP Measures to Non-GAAP Measures(In thousands) Three Months Ended September 30, 2025 2024 Reconciliation of GAAP to Non-GAAP Research and development expenses:GAAPResearch and development expenses358,814270,926Less:Stock-based compensation expenses (48,725) (19,794)Non-GAAPResearch and development expenses 310,089 $251,132Reconciliation of GAAPto Non-GAAP Selling,general and administrative expenses:GAAP Selling.general and administrative expensesS322,076 $220,993Less:Stock-based compensation expenses (59,486) (26,010)Non-GAAP Selling,general and administrative expenses S262,590 194,983Reconciliation of GAAPto Non-GAAPIncome(loss)from operations: | GAAPIncome(loss)from operations | S
367,982 | (76,905)
$ | | --- | --- | --- | | Add:Stock-based compensation expenses | 108,211 | 45,804 | | Non-GAAPOperating income (loss) | 476,193
$ | S
(31,101) | | Reconciliation of GAAPto Non-GAAPNet income(loss): | | | | GAAPNet income(loss) | S
251,084 | $
(111,570) | | Add:Stock-based compensation expenses | 108,211 | 45,804 | | Add:Realized and unrealized loss on marketable equity securities | 一 | 1,567 | | Add:Loss related to convertible debt | 39,146 | 一 | | Less:Income tax effect of GAAP to non-GAAP reconciling items | (2,261) | | | Non-GAAPNet income(loss) | 396,180
S( | (64,199)
$ | | Alnylam Pharmaceuticals,Inc. # Reconciliation of Product Revenue and Growth at Constant Currency September 30,2025 Three Months Ended Total TTR net product revenue growth,as reported135%Add:Impact of foreign currency translation (4)Total TTR net product revenue growth at constant currency131%Total Rare net product revenue growth,as reportedAdd:Impact of foreign currency translation (3)Total Rare net product revenue growth at constant currency11%Total net product revenue growth,as reported103%Add:Impact of foreign currency translation (4)Total net product revenue growth at constant currency 99%Total revenue growth,as reported149%Add:Impact of foreign currency translation(2)Total revenue growth at constant currency147% 14%

FAQs

What adjustments are used to reconcile GAAP research and development expenses to non-GAAP?

The reconciliation subtracts stock-based compensation expenses from GAAP research and development expenses to arrive at non-GAAP research and development expenses.

How is GAAP selling, general and administrative expense converted to non-GAAP?

The appendix deducts stock-based compensation expenses from GAAP selling, general and administrative expenses to produce non-GAAP selling, general and administrative expenses.

What does the constant-currency section measure and how is it derived?

It shows product revenue and growth metrics by starting with reported growth, adjusting for the impact of foreign currency translation, and then presenting the resulting growth at constant currency for multiple revenue categories.

Sep 3, 2026

Upload by wps_ap_test_251126_0180